PUMA BIOTECHNOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 105.65 thousand shares for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2024-11-07
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-09-30 was 0.00 shares.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2021-12-31 was 38.29K shares.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2021-09-30 was 37.87K shares.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2019-12-31 was 58.44K shares, a 176.12% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 186.34K shares.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2019 was 128.41K shares, a 30.15% decline from fiscal 2018.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2018 was 183.84K shares, a 35.58% decline from fiscal 2017.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2017 was 285.38K shares, a 36.09% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 105.65K shares 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | 105.65K shares 10-Q · filed 2024-08-01 | |||
| 2021-12-31 | 38.29K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | 76.16K shares derived: sum of 2 quarters · filed 2023-03-02 | 186.34K shares 10-K · filed 2023-03-02 | |
| 2021-09-30 | 37.87K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 148.05K shares 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | 110.18K shares 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | 58.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | 68.95K shares derived: sum of 2 quarters · filed 2021-03-01 | 78.64K shares derived: sum of 3 quarters · filed 2021-03-01 | 128.41K shares 10-K · filed 2021-03-01 |
| 2019-09-30 | 10.52K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 20.21K shares derived: sum of 2 quarters · filed 2019-11-07 | 69.97K shares 10-Q · filed 2019-11-07 | 91.13K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | 9.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | 59.45K shares 10-Q · filed 2019-08-09 | 80.62K shares derived: sum of 3 quarters · filed 2021-03-01 | 112.65K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | 49.76K shares 10-Q · filed 2019-05-10 | 70.92K shares derived: sum of 2 quarters · filed 2021-03-01 | 102.96K shares derived: sum of 3 quarters · filed 2021-03-01 | 152.99K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | 21.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | 53.20K shares derived: sum of 2 quarters · filed 2021-03-01 | 103.23K shares derived: sum of 3 quarters · filed 2021-03-01 | 183.84K shares 10-K · filed 2021-03-01 |
| 2018-09-30 | 32.03K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | 82.07K shares derived: sum of 2 quarters · filed 2018-11-05 | 162.67K shares 10-Q · filed 2018-11-05 | 175.65K shares derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | 50.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | 130.64K shares 10-Q · filed 2018-08-09 | 143.62K shares derived: sum of 3 quarters · filed 2020-02-28 | 193.59K shares derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | 80.60K shares 10-Q · filed 2018-05-10 | 93.58K shares derived: sum of 2 quarters · filed 2020-02-28 | 143.56K shares derived: sum of 3 quarters · filed 2020-02-28 | 305.48K shares derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | 12.98K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | 62.95K shares derived: sum of 2 quarters · filed 2020-02-28 | 224.88K shares derived: sum of 3 quarters · filed 2020-02-28 | 285.38K shares 10-K · filed 2020-02-28 |
| 2017-09-30 | 49.98K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | 211.90K shares derived: sum of 2 quarters · filed 2017-11-09 | 272.40K shares 10-Q · filed 2017-11-09 | 302.44K shares derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | 161.93K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | 222.42K shares 10-Q · filed 2017-08-09 | 252.47K shares derived: sum of 3 quarters · filed 2019-03-01 | 409.92K shares derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | 60.50K shares 10-Q · filed 2017-05-10 | 90.54K shares derived: sum of 2 quarters · filed 2019-03-01 | 248.00K shares derived: sum of 3 quarters · filed 2019-03-01 | 417.65K shares derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | 30.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | 187.50K shares derived: sum of 2 quarters · filed 2019-03-01 | 357.15K shares derived: sum of 3 quarters · filed 2019-03-01 | 446.54K shares 10-K · filed 2019-03-01 |
| 2016-09-30 | 157.46K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | 327.11K shares derived: sum of 2 quarters · filed 2016-11-09 | 416.50K shares 10-Q · filed 2016-11-09 | 479.53K shares derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-06-30 | 169.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | 259.05K shares 10-Q · filed 2016-08-09 | 322.08K shares derived: sum of 3 quarters · filed 2018-03-09 | 374.61K shares derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | 89.39K shares 10-Q · filed 2016-05-10 | 152.42K shares derived: sum of 2 quarters · filed 2018-03-09 | 204.96K shares derived: sum of 3 quarters · filed 2018-03-09 | 336.33K shares derived: sum of 4 quarters · filed 2018-03-09 |
| 2015-12-31 | 63.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | 115.56K shares derived: sum of 2 quarters · filed 2018-03-09 | 246.94K shares derived: sum of 3 quarters · filed 2018-03-09 | 277.14K shares 10-K · filed 2018-03-09 |
| 2015-09-30 | 52.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | 183.91K shares derived: sum of 2 quarters · filed 2015-11-09 | 214.11K shares 10-Q · filed 2015-11-09 | 352.43K shares derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | 131.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | 161.58K shares 10-Q · filed 2015-08-10 | 299.89K shares derived: sum of 3 quarters · filed 2017-03-01 | 302.39K shares derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | 30.20K shares 10-Q · filed 2015-05-11 | 168.51K shares derived: sum of 2 quarters · filed 2017-03-01 | 171.01K shares derived: sum of 3 quarters · filed 2017-03-01 | 191.01K shares derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | 138.32K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | 140.82K shares derived: sum of 2 quarters · filed 2017-03-01 | 160.82K shares derived: sum of 3 quarters · filed 2017-03-01 | 175.82K shares 10-K · filed 2017-03-01 |
| 2014-09-30 | 2.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | 22.50K shares derived: sum of 2 quarters · filed 2014-11-10 | 37.50K shares 10-Q · filed 2014-11-10 | 37.50K shares derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | 20.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | 35.00K shares 10-Q · filed 2014-08-11 | 35.00K shares derived: sum of 3 quarters · filed 2016-02-29 | 53.33K shares derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | 15.00K shares 10-Q · filed 2014-05-12 | 15.00K shares derived: sum of 2 quarters · filed 2016-02-29 | 33.33K shares derived: sum of 3 quarters · filed 2016-02-29 | |
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | 18.33K shares derived: sum of 2 quarters · filed 2016-02-29 | 19.86K shares 10-K · filed 2016-02-29 | |
| 2013-09-30 | 18.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | 19.86K shares 10-Q · filed 2013-11-12 | ||
| 2013-06-30 | 1.53K shares 10-Q · filed 2013-08-06 | |||
| 2012-12-31 | 30.00K shares 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |